Header Logo

Connection

Alan Landay to Viral Load

Back to Details
This is a "connection" page, showing publications Alan Landay has written about Viral Load.
Alan Landay
Connection Strength
3.678
Viral Load
  1. HIV RNA levels in plasma and cervical-vaginal lavage fluid in elite controllers and HAART recipients. AIDS. 2014 Mar 13; 28(5):739-43.
    View in: PubMed
    Score: 0.447
  2. Phospholipid Metabolism Is Associated with Time to HIV Rebound upon Treatment Interruption. mBio. 2021 02 23; 12(1).
    View in: PubMed
    Score: 0.181
  3. Monitoring HIV-1 treatment in immune-cell subsets with ultrasensitive fluorescence-in-situ hybridisation. Lancet. 1999 Jan 16; 353(9148):211-2.
    View in: PubMed
    Score: 0.156
  4. Effect of cytomegalovirus and Epstein-Barr virus replication on intestinal mucosal gene expression and microbiome composition of HIV-infected and uninfected individuals. AIDS. 2017 09 24; 31(15):2059-2067.
    View in: PubMed
    Score: 0.143
  5. The Association of Human Cytomegalovirus with Biomarkers of Inflammation and Immune Activation in HIV-1-Infected Women. AIDS Res Hum Retroviruses. 2016 Feb; 32(2):134-43.
    View in: PubMed
    Score: 0.125
  6. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis. 2014 Oct 15; 210(8):1248-59.
    View in: PubMed
    Score: 0.113
  7. Systematic review of the use of dried blood spots for monitoring HIV viral load and for early infant diagnosis. PLoS One. 2014; 9(3):e86461.
    View in: PubMed
    Score: 0.112
  8. Systematic review of the performance of HIV viral load technologies on plasma samples. PLoS One. 2014; 9(2):e85869.
    View in: PubMed
    Score: 0.111
  9. The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. Blood. 2013 Jun 06; 121(23):4635-46.
    View in: PubMed
    Score: 0.105
  10. Regulatory B cell frequency correlates with markers of HIV disease progression and attenuates anti-HIV CD8? T cell function in vitro. J Leukoc Biol. 2013 May; 93(5):811-8.
    View in: PubMed
    Score: 0.104
  11. Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. J Infect Dis. 2010 Jun 15; 201(12):1796-805.
    View in: PubMed
    Score: 0.086
  12. The relationship of T-regulatory cell subsets to disease stage, immune activation, and pathogen-specific immunity in HIV infection. J Acquir Immune Defic Syndr. 2008 Aug 15; 48(5):577-80.
    View in: PubMed
    Score: 0.076
  13. Positive association between HIV RNA and IL-6 in the genital tract of Rwandan women. AIDS Res Hum Retroviruses. 2008 Jul; 24(7):973-6.
    View in: PubMed
    Score: 0.075
  14. Immunophenotypic alterations in acute and early HIV infection. Clin Immunol. 2007 Dec; 125(3):299-308.
    View in: PubMed
    Score: 0.072
  15. Impact of class A, B and C CpG-oligodeoxynucleotides on in vitro activation of innate immune cells in human immunodeficiency virus-1 infected individuals. Immunology. 2007 Apr; 120(4):526-35.
    View in: PubMed
    Score: 0.069
  16. Evaluation of the impact of highly active antiretroviral therapy on immune recovery in antiretroviral naive patients. HIV Med. 2004 Jan; 5(1):55-65.
    View in: PubMed
    Score: 0.055
  17. Treatment of intestinal worms is associated with decreased HIV plasma viral load. J Acquir Immune Defic Syndr. 2002 Sep 01; 31(1):56-62.
    View in: PubMed
    Score: 0.050
  18. Sex Differences in Human Immunodeficiency Virus Persistence and Reservoir Size During Aging. Clin Infect Dis. 2022 08 24; 75(1):73-80.
    View in: PubMed
    Score: 0.050
  19. Time to Viral Rebound After Interruption of Modern Antiretroviral Therapies. Clin Infect Dis. 2022 03 09; 74(5):865-870.
    View in: PubMed
    Score: 0.049
  20. T-Cell Immune Dysregulation and Mortality in Women With Human Immunodeficiency Virus. J Infect Dis. 2022 02 15; 225(4):675-685.
    View in: PubMed
    Score: 0.048
  21. Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease. AIDS Res Hum Retroviruses. 2002 Jan 20; 18(2):95-102.
    View in: PubMed
    Score: 0.048
  22. Persistence of intracellular HIV-1 mRNA correlates with HIV-1-specific immune responses in infected subjects on stable HAART. AIDS. 2001 Sep 07; 15(13):1635-41.
    View in: PubMed
    Score: 0.047
  23. Effects of cocaine and HIV on decision-making abilities. J Neurovirol. 2021 06; 27(3):422-433.
    View in: PubMed
    Score: 0.046
  24. Food Insecurity and T-cell Dysregulation in Women Living With Human Immunodeficiency Virus on Antiretroviral Therapy. Clin Infect Dis. 2021 03 01; 72(5):e112-e119.
    View in: PubMed
    Score: 0.045
  25. Maintenance of Viral Suppression in Human Immunodeficiency Virus Controllers Despite Waning T-Cell Responses During Antiretroviral Therapy. J Infect Dis. 2020 11 09; 222(11):1837-1842.
    View in: PubMed
    Score: 0.044
  26. A look at HIV immune research. Interview by Alan Huff. Res Initiat Treat Action. 2000 Sep; 6(3):30-3.
    View in: PubMed
    Score: 0.044
  27. Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease. AIDS. 2000 May 05; 14(7):761-70.
    View in: PubMed
    Score: 0.043
  28. Antiretroviral Therapy Reduces T-cell Activation and Immune Exhaustion Markers in Human Immunodeficiency Virus Controllers. Clin Infect Dis. 2020 04 10; 70(8):1636-1642.
    View in: PubMed
    Score: 0.043
  29. Sialylation and fucosylation modulate inflammasome-activating eIF2 Signaling and microbial translocation during HIV infection. Mucosal Immunol. 2020 09; 13(5):753-766.
    View in: PubMed
    Score: 0.042
  30. Changes in human immunodeficiency virus type 1 virus load during mobilization and harvesting of hemopoietic progenitor cells. Adult AIDS Clinical Trials Group 285 Study Team. Blood. 2000 Jan 01; 95(1):48-55.
    View in: PubMed
    Score: 0.042
  31. Upregulation of IL-32 Isoforms in Virologically Suppressed HIV-Infected Individuals: Potential Role in Persistent Inflammation and Transcription From Stable HIV-1 Reservoirs. J Acquir Immune Defic Syndr. 2019 12 15; 82(5):503-513.
    View in: PubMed
    Score: 0.042
  32. A Randomized, Double-blinded, Placebo-controlled Trial of Sitagliptin for Reducing Inflammation and Immune Activation in Treated and Suppressed Human Immunodeficiency Virus Infection. Clin Infect Dis. 2019 09 13; 69(7):1165-1172.
    View in: PubMed
    Score: 0.041
  33. Soluble Urokinase Plasminogen Activator Receptor Is Predictive of Non-AIDS Events During Antiretroviral Therapy-mediated Viral Suppression. Clin Infect Dis. 2019 08 01; 69(4):676-686.
    View in: PubMed
    Score: 0.041
  34. Higher Anti-Cytomegalovirus Immunoglobulin G Concentrations Are Associated With Worse Neurocognitive Performance During Suppressive Antiretroviral Therapy. Clin Infect Dis. 2018 08 16; 67(5):770-777.
    View in: PubMed
    Score: 0.038
  35. Early reduction of immune activation in lymphoid tissue following highly active HIV therapy. AIDS. 1998 Jul 30; 12(11):F123-9.
    View in: PubMed
    Score: 0.038
  36. Frontline Science: Plasma and immunoglobulin G galactosylation associate with HIV persistence during antiretroviral therapy. J Leukoc Biol. 2018 09; 104(3):461-471.
    View in: PubMed
    Score: 0.037
  37. Higher Body Mass Index Is Associated With Greater Proportions of Effector CD8+ T Cells Expressing CD57 in Women Living With HIV. J Acquir Immune Defic Syndr. 2017 08 15; 75(5):e132-e141.
    View in: PubMed
    Score: 0.035
  38. The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon. Mucosal Immunol. 2018 03; 11(2):449-461.
    View in: PubMed
    Score: 0.035
  39. A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus. AIDS. 2016 Mar 27; 30(6):869-78.
    View in: PubMed
    Score: 0.032
  40. Gut dendritic cell activation links an altered colonic microbiome to mucosal and systemic T-cell activation in untreated HIV-1 infection. Mucosal Immunol. 2016 Jan; 9(1):24-37.
    View in: PubMed
    Score: 0.030
  41. Association of chronic hepatitis C infection with T-cell phenotypes in HIV-negative and HIV-positive women. J Acquir Immune Defic Syndr. 2014 Nov 01; 67(3):295-303.
    View in: PubMed
    Score: 0.029
  42. A randomized controlled trial of palifermin (recombinant human keratinocyte growth factor) for the treatment of inadequate CD4+ T-lymphocyte recovery in patients with HIV-1 infection on antiretroviral therapy. J Acquir Immune Defic Syndr. 2014 Aug 01; 66(4):399-406.
    View in: PubMed
    Score: 0.029
  43. Early microbial translocation blockade reduces SIV-mediated inflammation and viral replication. J Clin Invest. 2014 Jun; 124(6):2802-6.
    View in: PubMed
    Score: 0.028
  44. An altered intestinal mucosal microbiome in HIV-1 infection is associated with mucosal and systemic immune activation and endotoxemia. Mucosal Immunol. 2014 Jul; 7(4):983-94.
    View in: PubMed
    Score: 0.028
  45. Characterization of CD4? T-cell immune activation and interleukin 10 levels among HIV, hepatitis C virus, and HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr. 2013 Nov 01; 64(3):232-40.
    View in: PubMed
    Score: 0.027
  46. A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4? T-cell recovery despite sustained virologic suppression: ACTG A5256. J Infect Dis. 2012 Aug 15; 206(4):534-42.
    View in: PubMed
    Score: 0.025
  47. Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retroviruses. 2012 Oct; 28(10):1184-95.
    View in: PubMed
    Score: 0.024
  48. Interferon-alpha administration enhances CD8+ T cell activation in HIV infection. PLoS One. 2012; 7(1):e30306.
    View in: PubMed
    Score: 0.024
  49. The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women. AIDS. 2011 Sep 24; 25(15):1823-32.
    View in: PubMed
    Score: 0.024
  50. HIV-1 viruses detected during episodic blips following interleukin-7 administration are similar to the viruses present before and after interleukin-7 therapy. AIDS. 2011 Jan 14; 25(2):159-64.
    View in: PubMed
    Score: 0.022
  51. Intracellular Casp8p41 content is inversely associated with CD4 T cell count. J Infect Dis. 2010 Aug 15; 202(3):386-91.
    View in: PubMed
    Score: 0.022
  52. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood. 2009 Jun 18; 113(25):6304-14.
    View in: PubMed
    Score: 0.020
  53. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis. 2009 Apr 15; 199(8):1177-85.
    View in: PubMed
    Score: 0.020
  54. Enhanced antibody responses elicited by a CpG adjuvant do not improve the protective effect of an aldrithiol-2-inactivated simian immunodeficiency virus therapeutic AIDS vaccine. Clin Vaccine Immunol. 2009 Apr; 16(4):499-505.
    View in: PubMed
    Score: 0.020
  55. Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115. AIDS Res Hum Retroviruses. 2009 Feb; 25(2):135-9.
    View in: PubMed
    Score: 0.020
  56. PDL-1 upregulation on monocytes and T cells by HIV via type I interferon: restricted expression of type I interferon receptor by CCR5-expressing leukocytes. Clin Immunol. 2008 Oct; 129(1):132-44.
    View in: PubMed
    Score: 0.019
  57. In vitro cell-mediated immune responses of human immunodeficiency virus-infected and -uninfected individuals to whole cytomegalovirus antigens and their subunits. Clin Vaccine Immunol. 2008 Sep; 15(9):1398-409.
    View in: PubMed
    Score: 0.019
  58. Association of cells with natural killer (NK) and NKT immunophenotype with incident cancers in HIV-infected women. AIDS Res Hum Retroviruses. 2008 Feb; 24(2):163-8.
    View in: PubMed
    Score: 0.018
  59. Saliva can mediate HIV-1-specific antibody-dependent cell-mediated cytotoxicity. FEMS Immunol Med Microbiol. 2006 Nov; 48(2):267-73.
    View in: PubMed
    Score: 0.017
  60. Women with cervicovaginal antibody-dependent cell-mediated cytotoxicity have lower genital HIV-1 RNA loads. J Infect Dis. 2004 Dec 01; 190(11):1970-8.
    View in: PubMed
    Score: 0.015
  61. HIV-1-infected antiretroviral-treated patients with prolonged partial viral suppression: clinical, virologic, and immunologic course. J Acquir Immune Defic Syndr. 2003 Dec 15; 34(5):491-6.
    View in: PubMed
    Score: 0.014
  62. Can immune markers predict subsequent discordance between immunologic and virologic responses to antiretroviral therapy? Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003 Aug 15; 37(4):551-8.
    View in: PubMed
    Score: 0.013
  63. Entrapment of recent thymic emigrants in lymphoid tissues from HIV-infected patients: association with HIV cellular viral load. AIDS. 2002 Nov 08; 16(16):2119-27.
    View in: PubMed
    Score: 0.013
  64. The menstrual cycle does not affect human immunodeficiency virus type 1 levels in vaginal secretions. J Infect Dis. 2002 Sep 01; 186(5):726-8; author reply 728-9.
    View in: PubMed
    Score: 0.013
  65. Immune reconstitution after successful treatment with protease inhibitor-based and protease inhibitor-sparing antiretroviral regimens. J Acquir Immune Defic Syndr. 2002 Apr 15; 29(5):544-5.
    View in: PubMed
    Score: 0.012
  66. Antibody-dependent cell-mediated cytotoxicity in cervical lavage fluids of human immunodeficiency virus type 1--infected women. J Infect Dis. 2002 Feb 15; 185(4):439-47.
    View in: PubMed
    Score: 0.012
  67. T cell receptor excision circle (TREC) content following maximum HIV suppression is equivalent in HIV-infected and HIV-uninfected individuals. AIDS. 2001 Sep 28; 15(14):1757-64.
    View in: PubMed
    Score: 0.012
  68. Multiple CD4+ cell kinetic patterns and their relationships with baseline factors and virological responses in HIV type 1 patients receiving highly active antiretroviral therapy. AIDS Res Hum Retroviruses. 2001 Sep 01; 17(13):1231-40.
    View in: PubMed
    Score: 0.012
  69. A menstrual cycle pattern for cytokine levels exists in HIV-positive women: implication for HIV vaginal and plasma shedding. AIDS. 2001 Aug 17; 15(12):1535-43.
    View in: PubMed
    Score: 0.012
  70. Leukemia inhibitory factor inhibits HIV-1 replication and is upregulated in placentae from nontransmitting women. J Clin Invest. 2001 Feb; 107(3):287-94.
    View in: PubMed
    Score: 0.011
  71. Anti-CCR5 antibodies in sera of HIV-positive individuals. Hum Immunol. 2001 Feb; 62(2):143-5.
    View in: PubMed
    Score: 0.011
  72. Altered viral fitness of HIV-1 following failure of protease inhibitor-based therapy. J Acquir Immune Defic Syndr. 2000 Dec 01; 25(4):289-95.
    View in: PubMed
    Score: 0.011
  73. Effect of menstrual cycle on HIV-1 levels in the peripheral blood and genital tract. WHS 001 Study Team. AIDS. 2000 Sep 29; 14(14):2101-7.
    View in: PubMed
    Score: 0.011
  74. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team. J Infect Dis. 2000 Feb; 181(2):491-7.
    View in: PubMed
    Score: 0.011
  75. Alteration of complement protein levels after antiretroviral therapy in HIV-infected persons. AIDS Res Hum Retroviruses. 1999 Dec 10; 15(18):1713-5.
    View in: PubMed
    Score: 0.010
  76. HIV infection perturbs DNA content of lymphoid cells: partial correction after 'suppression' of virus replication. AIDS. 1999 Jul 09; 13(10):1177-85.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.